ProfileGDS5678 / 1417385_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 84% 83% 82% 80% 81% 85% 88% 84% 85% 82% 84% 82% 83% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.1514484
GSM967853U87-EV human glioblastoma xenograft - Control 26.153583
GSM967854U87-EV human glioblastoma xenograft - Control 36.0028882
GSM967855U87-EV human glioblastoma xenograft - Control 45.8571780
GSM967856U87-EV human glioblastoma xenograft - Control 55.8337181
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.1879685
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.6007888
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1878284
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.3880485
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.9560582
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.1385484
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.0643682
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.0324483
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.1798184